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1. IntroductIon 
jj Using new molecular and selective culture techniques, fungi have been detected in up to 
75% of CF patients, with some studies reporting a predominance of yeasts. Interestingly 
though, some microbiome analyses have challenged that fungal colonization is a common 
event in CF and suggested that the mycobiome may be dominated by transient species, 
present in the inhaled air. 
js Diversity of identified fungi has increased beyond Aspergillus fumigatus and Candida 
albicans to include other yeasts and filamentous fungi, particularly Scedosporium spp.
js Interspecies co-infection studies have revealed interdependence between bacteria and 
fungi and suggested, for example, inhibition of A. fumigatus and Scedosporium spp. 
growth by P. aeruginosa under specific conditions. 
jj In CF patients, the spectrum of host-fungi interactions in the respiratory tract includes 
js Colonization (common), hypersensitivity responses (less common) and fungal infection 
(uncommon). 
js The sites involved include the lungs but also the nasal passages and the paranasal 
sinuses.
jj colonization denotes the presence of fungi without clinical symptoms and radiological or 
laboratory signs of active disease. 
js Colonization poses two challenging questions in CF patients: 1) should any sign/ 
evolution of the lung disease be attributed to the presence of fungi and 2) does the 
fungal presence influence growth of other potential pathogens. 
js As a result, the overall effect of fungal colonization on the progression of CF-disease 
remains unclear.
jj Hypersensitivity responses range from IgE-mediated sensitization (asthma) to immune 
complex and delayed hypersensitivity (allergic bronchopulmonary mycosis).
jj The term fungal infection includes:
js Fungal bronchitis: currently the only form described is “Aspergillus bronchitis” (rare).
js Aspergilloma (very rare).
js Invasive fungal disease (very rare).
2. tHe spectrum of fungI 
jj A wide range of fungi have been identified in CF, with variable frequency/chronicity and 
pathogenicity (figure 1). The most frequently isolated filamentous fungi are A. fumigatus 
and Scedosporium ssp, and yeast, C. albicans.
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2.1 Aspergillus fumigatus
jj A. fumigatus is the most commonly isolated filamentous fungus in CF (prevalence 
approx. 30%). This ubiquitous saprophytic fungus reaches the distal airways by inhalation 
of airborne Aspergillus conidia. The abnormal mucus and the defective airway clearance 
observed in CF facilitate the establishment of Aspergillus in the lungs.
jj Baxter et al. described 4 distinct classes of aspergillosis in CF based on the assessment of 
sputum galactomannan, real-time PCR (RT-PCR) and serologic markers (table 1). 
js This is the only CF-specific classification currently available in the literature, however 
it remains controversial and requires validation before it can be used in the clinical 
setting. 
js This classification illustrates the different clinical phenotypes associated with Aspergillus 
in CF, but its predictive value for patient outcomes has not been evaluated yet. 
Furthermore, it relies on sputum galactomannan testing, which is not readily available 
and for which the role in the diagnosis of ABPA or aspergillus infection remains debated. 
2.1.1 colonization
jj The role of Aspergillus colonization in the progression of CF-lung disease is unclear. 
Inconsistent and conflicting results have been published about its effect on the frequency 
of exacerbations and the rate of FEV1 decline.
figure 1: Cystic fibrosis fungal biodiversity. The frequency of isolation is depicted 
in the x axis and the established pathogenicity on the y axis. The fungi are further 
divided according to their chronicity. The most frequently isolated filamentous 
fungi (A. fumigatus and Scedosporium spp.) and yeast (Candida albicans) are 
highlighted. reprinted with permission of the American thoracic society. 
copyright® 2017 American thoracic society. chmiel et al. Ann Am thorac 
soc 2014; 11 (8): 1298–13061. Annals of the American thoracic society is an 
official journal of the American thoracic society.
34.3.7 FUNGI
table 1: Classes of aspergillosis proposed by Baxter et al.2a
sputum rt-pcrb Blood immunologic 
markers
sputum 
galactomannanc
Class I (non-diseased) Positive or negative Negative Negative
Class II (serologic 
ABPA)
Positive Increased total and speci-
fic A. fumigatus IgE/IgG
Positive
Class III (A. fumigatus 
sensitized)
Positive or negative Increased A. fumigatus IgE 
(but not IgG)
Negative
Class IV (A. fumigatus 
bronchitis)
Positive Increased A. fumigatus IgG 
(but not IgE)
Positive
Abbreviations: ABPA=allergic bronchopulmonary aspergillosis, RT-PCR=real time PCR
a This classification needs validation before it can be used in clinical practice. 
b This analysis is not part of routine investigations and is not readily available. 
c In the study of Baxter et al., a sputum galactomannan index >0.5 had a sensitivity of 98% and a specificity of 96% 
to differentiate classes II+IV from classes I+III. However, this analysis is not standardized and not readily available in 
clinical practice.
jj Interventional studies, regarding antifungal treatment in this setting, are difficult to design 
and yielded conflicting results. 
jj Currently, no definite evidence exists that would favor targeted antifungal treatment or that 
would allow general recommendations in this setting. The decision to treat with an antifun-
gal agent should be made:
js on an individual basis (evidence of lung function decline that cannot be attributed to 
another cause) and 
js after consideration of the individual risks (interactions, side-effects, development of 
resistance).
2.1.2 Hypersensitivity responses 
jj CF patients can develop IgE-mediated sensitization to Aspergillus (table 1, Class III 
 according to Baxter et al).
jj Allergic bronchopulmonary aspergillosis (ABPA), the most common form of allergic 
 bronchopulmonary mycosis (prevalence in CF 2-15%), is an immune response against 
A. fumigatus resulting in inflammation and decreased lung function in CF patients. For 
more details see  chapter  “ABpA”.
2.1.3 Aspergillus bronchitis
jj This recently described clinical entity has not been clearly defined in the literature and is a 
diagnosis of exclusion. 
jj It is based on the observation that some CF patients with repeatedly positive cultures for 
Aspergillus and concomitant symptoms of exacerbation do not respond to antibiotics but 
improve with antifungal therapy. 
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jj It refers to a non-invasive (“superficial”, “mucosal”) Aspergillus infection of the lower airways 
characterized by the findings described in table 2. The reported prevalence is 1.6-9%.
jj Although it can be assumed that other fungi may also cause similar manifestations, 
currently, in adult CF patients, this type of bronchitis has been recognized only for 
Aspergillus.
table 2:  Findings indicating the presence of Aspergillus bronchitis  
(adapted from 2,3)
Persistently increased (>4 weeks) respiratory symptoms or recurrent 
respiratory exacerbations 
Repeated identification of Aspergillus in sputum (by culture or RT-PCR*)
Increased A. fumigatus IgG (but not IgE)
Positive sputum galactomannan*
No evidence of invasive fungal disease 
Lack of response to appropriate antimicrobial therapy 
Good response to antifungal therapy
RT-PCR: reverse transcription-polymerase chain reaction
* These analyses are not part of routine investigations and they are not readily available.
Note: Bronchoscopic findings are non-specific and are commonly observed in CF patients even without fungal 
 bronchitis. These include tenacious sputum, mucoid impaction/plugging, erythema, fragile mucosa that bleeds easily, 
ulceration, superficial invasion of the mucosa by fungal hyphae.
2.1.4 Aspergilloma (mycetoma, fungal ball)
jj A rare presentation that occurs in previously damaged areas of the lungs (e.g. cavities, 
bronchiectasis).
jj Complications include: progressive destruction of the pulmonary parenchyma with 
 necrosis and cavitation, vascular erosion leading to massive hemoptysis, and rarely, pro-
gression to invasive fungal infection.
2.2 scedosporium spp.
jj The taxonomy of Scedosporium spp. (teleomorph/sexual state called Pseudallescheria) 
has evolved over the last years. Currently the term Scedosporium apiospermium com-
plex is used for five closely related species, four of which have been described in CF: a) 
S. apiospermum, b) S. boydii, c) S. aurantiacum, and d) S. minutispora. S. prolificans has 
been renamed as Lomentospora prolificans. 
jj Their prevalence in CF is 3-10%, but a recent study reported a high rate of false negative 
cultures on non-selective medium, mainly with concomitant growth of A. fumigatus.
jj Scedosporium spp. can result in colonization, hypersensitivity responses or invasive infec-
tion. Especially after lung transplantation, this fungus can cause invasive, disseminated 
infection associated with high mortality. 
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2.2.1 colonization 
jj Little is known about the factors associated with Scedosporium spp. colonization: 
one study has shown that patients colonized with mucoid P. aeruginosa were less 
likely to be colonized with Scedosporium spp., whereas previous treatment with anti- 
staphylococcal penicillins was a risk factor for Scedosporium colonization. Another 
study showed that potted plants were a reservoir increasing the risk for Scedosporium 
colonization.
jj Eradication is difficult and potentially not achievable. However, given the risk of invasive 
disease especially after transplantation, an eradication attempt should be considered for 
transplant candidates (see paragraph 5.1 “treatment”).
2.2.2 Hypersensitivity responses 
jj Hypersensitivity responses: S. apiospermium has been associated with allergic broncho-
pulmonary disease.
2.3 candida albicans
jj C. albicans is very frequently isolated from the respiratory tract of CF patients (up to 75% 
of respiratory samples). 
jj Its role in the progression of CF-lung disease is not clearly established. A few observational 
studies suggested that C. albicans colonization was associated with a higher exacerbation 
rate and an accelerated decline of FEV1 and BMI. 
2.3.1 colonization
jj Predisposing factors for colonization of the respiratory tract with C. albicans include 
 exposure to antibiotics, inhaled corticosteroids and CFRD.
jj As its isolation is very common in CF, and its role in the progression of CF-lung disease not 
clearly established, preemptive antifungal treatment is not recommended. 
2.3.2 Hypersensitivity responses
jj Sensitization to C. albicans has not been associated with pulmonary exacerbations or a 
decline in FEV1. Allergic bronchopulmonary candidiasis has been rarely reported (non-CF 
case reports, some with concomitant Aspergillus hypersensitivity).
3. fungAl rHInosInusItIs
jj Rhino-sinus isolation of fungi, especially A. fumigatus, is common in CF (up to 40% of 
patients) and suggests colonization in the vast majority of cases. 
jj Fungal rhinosinusitis refers to a group of entities including mycetoma (fungal ball), allergic 
fungal rhinosinusitis (AFS) and invasive fungal rhinosinusitis. 
jj AFS is considered a distinct form of chronic rhinosinusitis. Its prevalence is unknown 
in CF (in the non-immunocompromized CF population, there is only case report 
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evidence), but in the general population it accounts for about 5-10% of chronic rhinosinu-
sitis cases.
js It has been described as the upper airway equivalent of allergic bronchopulmonary 
mycosis (such as ABPA), but the two entities have some differences (e.g. in AFS total 
IgE is moderately elevated, precipitins may not be positive) and it is extremely uncom-
mon for the two conditions to coexist. 
js AFS is difficult to diagnose because it develops slowly and, unless complications deve-
lop, it presents with symptoms similar to the other forms of chronic rhinosinusitis. 
js It is associated with the presence of eosinophilic mucin (macroscopically thick, brown or 
black coloured mucous, microscopically presence of fungal hyphae and degranulating 
eosinophils). 
4. InvAsIve fungAl InfectIons
jj Invasive fungal infections (IFI) are rare in CF patients before transplantation and their 
diagnosis is challenging.
js Aspergillus spp and Scedosporium spp can cause invasive infections, especially after 
transplantation in the setting of immunosuppression. 
js In CF, there are case reports of catheter-related, Candida ssp blood stream 
infections.
jj Imaging (CT scan) and histopathological proof of tissue invasion are crucial. 
jj No CF-specific guidelines for the diagnosis of IFI have been established. 
js As in solid organ transplantation, the European Organization for Research and Treatment 
of Cancer (EORTC) consensus definitions, originally designed for neutropenic patients, 
can be applied for diagnosis, but this should be done with caution as they have never 
been formally validated in the non-neutropenic CF-population. In these guidelines, 3 
diagnostic categories are used: possible, probable, proven IFI.
js A recent review (Schwarz C et al. 2017) focusing on CF-patients described a group of 
findings that together suggested IFI and was tentatively categorized as “highly  probable” 
IFI. This new category is based on expert-opinion without epidemiological confirmation, 
and should be used with caution, since it has not been validated yet. 
5. treAtment 
jj table 3 gives examples of available antifungal agents, their dosage in CF and some 
special considerations.
jj role of antifungal susceptibility testing: The incidence of azole resistance is rising in 
Aspergillus spp. in the setting of extended use of azoles in agriculture. Therefore, suscepti-
bility testing should be obtained whenever feasible. Susceptibility testing is recommended 
at treatment initiation for:
js patients at risk for resistant fungi (e.g. previous treatment with an antifungal agent, all 
cases of Scedosporium spp.)
js before modification of antifungal therapy (e.g. in cases of poor response to the initial 
treatment). Given the fact that treatment failures occur despite in vitro activity, guidance 
by an infectious disease expert should be obtained.
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5.1 treatment of colonization
jj for fungi other than scedosporium spp.: the scarcity and contradictory nature of avai-
lable data does not allow a general recommendation on preemptive antifungal therapy 
in this setting. Given the caveats such as development of resistance, side effects and 
potential drug interactions (both frequent with azoles), the decision to treat with antifungals 
should be made on an individual basis with great caution. 
jj for scedosporium spp.: due to the increased risk of invasive disease especially 
after transplantation, an eradication attempt should be considered for transplant 
candidates balancing the risks and benefits of treatment. 
js Treatment choice should be based on antifungal susceptibility testing. Scedosporium 
is resistant to amphotericin B and occasionally resistant to azoles. Therefore,  surgical 
 debridement of infectious foci should be considered on a case-by-case basis and 
performed whenever feasible. Voriconazole has the lowest minimum inhibitory concen-
tration (MIC) against Scedosporium spp. Posaconazole, isavuconazole and echino-
candins have a moderate activity against some Scedosporium strains. Azoles and 
 echinocandins may have a synergistic effect against Scedosporium. Lomentospora 
 proliferans is potentially resistant to all antifungal agents.
js For eradication, voriconazole is given orally (loading dose 400 mg every 12h for two 
doses, and then 200 mg 2x/day) as monotherapy. An initial phase of IV voriconazole treat-
ment may be considered (see table 3). Treatment duration should be for a minimum of 
4 weeks and adapted individually according to the persistence of Scedosporium in res-
piratory samples. Treatment adherence should be assessed regularly. In the absence of 
eradication, prolonged exposure (>3 months) to voriconazole during preemptive therapy 
should be avoided due to the increased risk of squamous cell carcinoma. Therapeutic 
drug monitoring (TDM) is recommended routinely for voriconazole use. For general re-
commendations regarding patient monitoring during voriconazole treatment see table 3. 
For TDM recommendations see chapter “therapeutic drug monitoring”.
js Bronchoalveolar lavage (BAL) cultures may provide guidance regarding treatment dura-
tion, with negative cultures on two different occasions suggesting successful eradication. 
js No data are available for an optimal surveillance strategy following an eradication at-
tempt, however increasing the frequency of sputum cultures (once per month) for the 
first months after eradication is recommended. Surveillance bronchoscopy with BAL 
may also be considered for selected cases.
5.2 treatment of ABpA
jj Treatment of ABPA is detailed in chapter “ABpA”.
5.3 treatment of Aspergillus bronchitis
jj Limited evidence has been published to allow general recommendations concerning 
choice of antifungal agents and treatment duration:
js Azoles (itraconazole or voriconazole) are considered the first line treatment. 
j Note: to date, there are only limited data on the use of isavuconazole in the CF-population 
but it might be an alternative in case of side effects or drug interactions.
js Susceptibility testing is recommended before treatment initiation and in case of insuffi-
cient response to treatment to assess antifungal resistance.
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table 3: Examples of systemic and inhaled antifungal agents and their dosage in non-transplanted CF patients 
Agent usual dosage comments
Oral Itraconazole 5mg/kg/day (max 600 mg/day)
When daily dose exceeds 200 
mg/day administer 2x/day
– Only for non-invasive fungal infection
– Monitor liver function tests, QT-interval, drug interactions
– Limited and individualized bioavailability: 
a) Preferential use of the liquid formulation
b)  For the liquid formulation: administration on an empty 
 stomach, concomitant administration with a low pH drink  
(e.g. orange juice, coca cola) and avoidance/spaced use of 
acid-blocking agents and proton pump inhibitors.
c) For capsules: administration with food
– TDM is recommended
Voriconazole Loading dose 400 mg every 
12h for two doses, and then 
200 mg 2x/day
–  Alternative to itraconazole (improved gastrointestinal tolerance, 
bioavailability)
– First choice for invasive aspergillosis
–  Monitor liver function tests, visual disturbances, photosensitivity, 
QT-interval, drug interactions. Prolonged voriconazole exposure 
has been associated with increased risk for skin cancer.
– Take on empty stomach (1 hour before or 1 hour after meal)
– TDM is recommended
Posaconazole Delayed-release tablets: 
Loading dose 300 mg every 
12h for two doses, and then 
300 mg 1x/day 
Solution:  200 mg 3-4 x/day
–  Very poor bioavailability of solution, always favor delayed-release 
tablets. As this affects dosing, always specify on prescription 
whether the dose refers to tablets or solution.
–  For the solution, improve bioavailability by: adding high fat meal 
and acid liquid drinks, fractionating dosing 3-4 x/day
– Monitor liver function tests, QT interval, drug interactions
– TDM is recommended
– off-label use
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Isavuconazole Loading dose 200 mg every 
8h for two days (6 doses), and 
then 200 mg 1x/day 
–  Compared to other azoles: good bioavailability, less drug interac-
tions, reduced liver toxicity
–  No data on the necessity of TDM so far; if available could be 
performed but not required
IV L-AMB
(AmBisome®)
3 mg/kg/day – Only for invasive diseases
–  Given kidney toxicity always request infectious disease specialist 
advice
– Monitor renal function, electrolytes, liver enzymes
–  Dosing of L-AMB differs from the one used for AMB-d (attention 
during prescription)
Voriconazole Loading dose 6mg/kg every 
12h for two doses, and then  
4 mg/kg every 12h
–  Contains cyclodextrin which accumulates in those with renal 
insufficiency, therefore the IV formulation should not be used 
with renal clearance below 50 ml/min
 – Monitor liver function tests, renal function, visual disturbances, 
photosensitivity, drug interactions and QT prolongation
– TDM is recommended
Posaconazole Loading dose 300 mg every 
12h for two doses, and then 
300 mg 1x/day 
–  Contains cyclodextrin which accumulates in case of renal insuffi-
ciency, therefore the IV formulation should not be used with renal 
clearance below 50 ml/min
– Monitor liver function tests
– TDM is recommended
off-label use
Isavuconazole Loading dose 200 mg every 
8h for two days (6 doses), and 
then 200 mg 1x/day 
–  Compared to other azoles: good bioavailability, less drug interac-
tions, reduced liver toxicity
–  Does not contain cyclodextrin and can be used in case of renal 
insufficiency
–  No data on the necessity of TDM so far; if available could be 
performed but not required
(continued)
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Agent usual dosage comments
Caspofungin Loading dose 70 mg 1x/day for 
day 1 and then 50 mg 1x/day 
– Second line antifungal agent for Aspergillus
– Very low liver toxicity 
may be off-label (depends on the indication)
Anidulafungin Loading dose 200 mg 1x/day 
for day 1 and then 100 mg 1x/
day
– Second line antifungal for Aspergillus
– Very low liver toxicity
may be off-label (depends on the indication)
Nebulized L-AMB 
(AmBisome®)
25 mg twice a day 3 days/week 
in the first month and then 2 
days/week 
[50 mg in 12 ml of WFI (4mg/
ml) � nebulisation using a 
dedicated jet nebulizer such as 
PARI-Turboboy® over 15 min]
–  Bronchospasm may occur. It is recommended to perform spi-
rometry before and after administration of the first dose, and to 
administer bronchodilators before each dose.  
–  Dosing of L-AMB differs from the one used for AMB-d (attention 
during prescription)
– Incompatible with NaCl: reconstitution with WFI only!
–  Reconstituted L-AMB can be stored for a maximum of 24h at 2-8°C.
Conventional 
AMB-d 
(Fungizone®)
10 mg twice a day 3 days/week 
[50 mg of AMB-d dissolved in 
10 ml of WFI (5mg/ml) � nebu 
lisation of 10mg (2ml) using 
a dedicated such as PARI-
Turboboy® over 15 min]
–  Bronchospasm may occur. It is recommended to perform spi-
rometry before and after administration of the first dose, and to 
administer bronchodilators before each dose. 
–  Dosing of AMB-d differs from the one used for L-AMB (attention 
during prescription) 
– Incompatible with NaCl: reconstitution with WFI only!
–  Reconstituted AMB-d can be stored for a maximum of 7 days 
at 2-8°C. 
off-label use
AMB-d=amphotericin B deoxycholate, L-AMB= liposomal amphotericin B, TDM=therapeutic drug monitoring, WFI=water for injection
Details on TDM can be found in the chapter “therapeutic drug monitoring”
114.3.7 FUNGI
js A clinical response after 2-8 weeks of antifungals may support the diagnosis of 
Aspergillus bronchitis. A high rate of relapse has been described in some patients 
requiring long-term therapy (to be balanced with the risk of skin cancer with prolonged 
voriconazole exposure).
5.4 treatment of Aspergilloma 
jj Treatment should be discussed on an individual basis taking into account the risks and 
benefits of medical, surgical or intra-lesional management. 
jj The indication for bronchial-artery embolization, to prevent or to treat hemoptysis, should 
be assessed in collaboration with an experienced interventional radiologist. 
jj Factors to be considered include: severity of the underlying pulmonary disease, location and 
progression of aspergilloma (increases in size), presence of local invasion (e.g. “halo sign” 
on chest-CT scan, referring to a ground glass area surrounding a nodular opacity, and posi-
tive galactomannan assay in the blood), and the risk for complications such as hemoptysis. 
5.5 treatment of invasive fungal infections
jj IFI should be treated in collaboration with an infectious disease expert according to the 
current available guidelines (Patterson et al. 2016).
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